Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 6/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.34 |
| ▸ | ACACB | O00763 | 4/20 | 0.34 |
| ▸ | ACACA | Q13085 | 4/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20186606 | 0.80 | CAMK2D (0.43) | CACNA1IKCNH2PRMT5 | |
| SCHEMBL20186604 | 0.80 | CAMK2D (0.43) | CACNA1IKCNH2PRMT5 | |
| SCHEMBL20186601 | 0.80 | CAMK2D (0.43) | CACNA1IKCNH2PRMT5 | |
| SCHEMBL20206901 | 0.79 | CAMK2D (0.57) | KCNH2 | |
| SCHEMBL20202166 | 0.75 | LMNA (0.37) | PIK3CAKMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL20206899 | 0.75 | EGLN2 (0.37) | PIK3CAALDH1A1KDM4ELMNA | |
| SCHEMBL20225504 | 0.71 | CAMK2D (0.42) | CACNA1IKCNH2 | |
| SCHEMBL20225618 | 0.70 | CAMK2D (0.41) | KCNH2PRMT5WDR77PIK3CA | |
| SCHEMBL20202159 | 0.65 | HTR3E (0.43) | KMT2AALDH1A1MEN1 | |
| SCHEMBL13590839 | 0.64 | ACACB (0.65) | CACNA1IKCNH2ACACBACACAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3548495-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | CAMK1, CAMKK1, CAMK1D | CACNA1I 249/4885KCNH2 388/4885ACACB 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.